BIOMAT Database Logo BIOMAT Database Logo

Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience. 1993

D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Service d'Oncologie Médicale, Hôpital de la Salpétrière, Paris, France.

Optimistic results were obtained in the treatment of 39 patients with surgically incurable metastatic malignant melanoma using a regimen including 2 to 3 monthly induction cycles of cis-diamminedichloroplatinum (CDDP), recombinant interleukin-2 (rIL-2) and interferon alpha-2a (IFN alpha-2a). 33 of 39 patients were pretreated with chemotherapy (dacarbazine and/or fotemustine:31, CDDP:6) and 17 of 39 with IFN alpha-2a. Overall response rate was 54% with 13% achieving a complete response for up to 59+ weeks. Moderate to severe side-effects were reversible on rIL-2 cessation and toxicity was manageable in a routine inpatient setting. These results are especially encouraging as they were seen in previously treated patients, classically low responders, including 3 who were resistant to cisplatin or other platinum complexes. The question remains if this regimen bypasses traditional mechanisms of drug resistance.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
January 2007, The Cochrane database of systematic reviews,
D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
WITHDRAWN: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
February 2018, The Cochrane database of systematic reviews,
D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
June 2005, Melanoma research,
D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma.
August 1997, European journal of cancer (Oxford, England : 1990),
D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Letter: Chemoimmunotherapy of malignant melanoma.
January 1975, The New England journal of medicine,
D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Sequential chemoimmunotherapy for metastatic melanoma.
October 1991, Seminars in oncology,
D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
May 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
August 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
February 1997, Seminars in oncology,
D Khayat, and E Antoine, and O Rixe, and J M Tourani, and E Vuillemin, and C Borel, and A Benhammouda, and L Thill, and C Franks, and G Auclerc
Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
August 1993, Melanoma research,
Copied contents to your clipboard!